MRX-8 is under clinical development by MicuRx Pharmaceuticals and currently in Phase I for Acinetobacter Infections. According to GlobalData, Phase I drugs for Acinetobacter Infections does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the MRX-8 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
MRX-8 overview
MRX-8 is under development for the treatment of multi-drug resistant gram negative bacterial infections which include Escherichia coli, Pseudomonas aeruginosa, Klebsiella pneumoniae Infections and Acinetobacter baumannii. It is administered through intravenous route. The drug candidate is a polymyxin derivative. Polymyxin is an antibiotic obtained from the Paenibacillus polymyxa bacteria source.
MicuRx Pharmaceuticals overview
MicuRx Pharmaceuticals (MicuRx) is a biopharmaceutical company that focuses on novel therapeutics for infectious diseases. The company pipeline products include contezolid (MRX-I), MRX-4 which treats drug-resistant gram-positive bacterial infection; MRX-8, MRX-5, MRX-7 for drug-resistant bacterial infection; MRX-15, MRX-17 treats kidney disease; MRX-18 for corona virus infection; MRX-23 treats tumors. It also develops antibiotics. The company has its operations in the US and China. MicuRx is headquartered in Foster City, California, the US.
For a complete picture of MRX-8’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
